2026-06-14T03:56:07Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/160502025-04-30T12:41:24Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16988
Repisalud
author
Rodríguez-Mora, Sara
author
Pérez-Lamas, Lucía
author
Sainero, Miriam Solera
author
Torres, Montserrat
author
Sánchez-Menéndez, Clara
author
Corona, Magdalena
author
Mateos, Elena
author
Casado-Fernández, Guiomar
author
Alcamí, José
author
García-Pérez, Javier
author
Perez-Olmeda, Mayte
author
Murciano-Antón, María Aranzazu
author
López-Jiménez, Javier
author
García-Gutiérrez, Valentín
author
Coiras, Mayte
funder
Instituto de Salud Carlos III
funder
Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
funder
Ministerio de Ciencia e Innovación (España)
funder
National Institutes of Health (Estados Unidos)
funder
Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)
funder
Instituto Ramón y Cajal de Investigación Sanitaria (España)
2023-05-11T08:13:29Z
2023-05-11T08:13:29Z
2023-02
Cancers. 2023,15:2344.
10.3390/cancers15082344
2072-6694
Cancers
http://hdl.handle.net/20.500.12105/16050
The high morbimortality due to SARS-CoV-2 infection in oncohematological diseases (OHD) and hematopoietic stem cell transplant (HSCT) recipients in the pre-vaccine era has made vaccination a priority in this group. After HSCT, the immune responses against common vaccines such as tetanus, varicella, rubella, and polio may be lost. However, the loss of immunity developed by COVID-19 vaccination after HSCT has not been completely defined. In this study, both humoral and cellular immunity against SARS-CoV-2 were analyzed in 29 individuals with OHD who were vaccinated before receiving allogeneic (n = 11) or autologous (n = 18) HSCT. All participants had low but protective levels of neutralizing IgGs against SARS-CoV-2 after HSCT despite B-cell lymphopenia and immaturity. Although antibody-dependent cellular cytotoxicity was impaired, direct cellular cytotoxicity was similar to healthy donors in participants with autologous-HSCT, in contrast to individuals with allogeneic–HSCT, which severely deteriorated. No significant changes were observed in the immune response before and after HSCT. During follow-up, all reported post-HSCT SARS-CoV-2 infections were mild. This data emphasizes that COVID-19 vaccination is effective, necessary, and safe for individuals with OHD and also supports the persistence of some degree of immune protection after HSCT, at least in the short term, when patients cannot yet be revaccinated.
eng
COVID-19 vaccine
Autologous transplantation
Allogeneic transplantation
Cytotoxic response
Humoral response
Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination
research article
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
URL
https://repisalud.isciii.es/bitstreams/134a9b80-d1ab-4d6a-8c22-b7f22f206912/download
File
MD5
b5478d40cc32aab64e5154df399f29a4
1950533
application/pdf
PersistentImmunityAgainstSARS-CoV-2_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/3421d8fe-2be3-497a-8528-3b1535eb47a7/download
File
MD5
bbec92cc0270a51b7c5d981d26e5e99f
365911
application/pdf
TableS1_PersistentImmunityAgainstSARS-CoV-2_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/bf8a1d8f-a9a5-4579-a0d6-36963cee0dbb/download
File
MD5
74a1d08bbba62718c8d74ca8838990ce
32318
application/pdf
TableS2_PersistentImmunityAgainstSARS-CoV-2_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/25ac4591-4590-4a5c-82a4-113f8ce530ca/download
File
MD5
4c6dfd48796057656e6869b1f5b1091c
138212
application/pdf
FigureS1_PersistentImmunityAgainstSARS-CoV-2_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/a683289d-b712-46e7-b53b-bdd363768af2/download
File
MD5
caefa06e8bf2154921180199f5186f20
68250
text/plain
PersistentImmunityAgainstSARS-CoV-2_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/c6f11705-209e-4715-b218-175cfd16dd27/download
File
MD5
b2a6e4f74a31fe76be24e17e2055d15b
5761
text/plain
TableS1_PersistentImmunityAgainstSARS-CoV-2_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/6880837b-2f2e-4167-9a3f-37f47a6589ea/download
File
MD5
ed0af57250cbffab16ebde1d0874e5f5
1492
text/plain
TableS2_PersistentImmunityAgainstSARS-CoV-2_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/b95abc17-c871-4e7c-9c52-5cf5afa5226f/download
File
MD5
ba65928189ec87bd643e55cd76b54b4c
1254
text/plain
FigureS1_PersistentImmunityAgainstSARS-CoV-2_2023.pdf.txt